Skip to main content

Table 3 Percentage and number of persistent vs. non-persistent patients per quartile of predicted scores based on baseline MSQoL-54 Physical and MSSES Control scores

From: Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study)

Quartile

Percentage non-persistent patients

Percentage persistent patients

N total

4

23.40 (n = 11)

76.60 (n = 36)

47

3

25.00 (n = 12)

75.00 (n = 36)

48

2

46.81 (n = 22)

53.19 (n = 25)

47

1

53.19 (n = 25)

46.81 (n = 22)

47

Total

37.04 (n = 70)

62.96 (n = 119)

189

  1. MSQoL-54 Multiple Sclerosis Quality of Life-54, MSSES Multiple Sclerosis Self-Efficacy Scale; Χ 2 = 13.91, p = 0.0030